Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

Investigators compared outcomes among patients with psoriasis undergoing apremilast treatment with genital involvement versus those without genital involvement.

Can-Fite BioPharma (CANF) initiated a pivotal phase 3 psoriasis study of its oral drug Piclidenoson with the U.S. Food and Drug Administration ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development of the former’s ...